Business Wire

THALES

5.6.2024 11:44:26 CEST | Business Wire | Press release

Share
Thales Now Provides Complete Passwordless Functionality for Enterprises with Passwordless 360°

Thales, the leading global technology and security provider, today announced Passwordless 360°, a new concept for passwordless authentication which offers Thales customers the broadest coverage of passwordless function across multiple types of users and assurance levels. Passwordless 360° has the flexibility to let companies use the latest technologies like FIDO passkeys, while also making the most of previous investments they might have made in passwordless technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605617393/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©KuppingerCole

End users are increasingly frustrated with the number of passwords they’re asked to use, as well as the rules in place around their complexity. With the average person having as many as 100 to manage, users seek workarounds to get by – choosing passwords that are easier to remember or reusing the same password across multiple services.

Passwordless 360° provides a complete set of tools that let organizations use passwordless authentication across a wide range of applications - from secure access to personal and work devices, to legacy and modern web resources. This helps keep the costs of making the move to passwordless down by being able to use one system – as well as increasing the likelihood that employees, customers and suppliers will use it. By removing the need to use traditional passwords it also eliminates the associated security risks through theft and phishing. Passwordless 360° can also meet the individual risk management requirements an organization might have, adhering to NIST requirements no matter where the passkeys are stored.

Sitting alongside the existing Thales OneWelcome Identity Platform that serves as the foundation for passwordless policies, the Passwordless 360° concept includes:

  • Support for passkeys in the OneWelcome Identity Platform
  • Passwordless Windows Logon, a true passwordless user experience that replaces passwords with ways for users to identify themselves, offering convenience and security benefits.
  • SafeNet FIDO Key Manager, a way of helping users manage the several FIDO keys they might be using themselves, reducing administration costs for organizations.
  • FIDO Authenticator Lifecycle Management, developed in partnership with identity management software company Versasec. This tool lets organizations manage FIDO tokens and lets larger enterprises make the move to the modern FIDO standard at the scale needed.

The announcement comes as Thales has been named an Overall, Product, Innovation and Market Leader in KuppingerCole’s latest Leadership Compass on Passwordless Authentication for Consumers, with the platform praised for offering a versatile set of identity applications encompassing a wide range of authentication methods to meet organizations’ needs.

Alejandro Leal, Research Analyst at KuppingerCole commented: Overall, Thales offers a comprehensive solution that enables organizations to improve their identity management practices, adapt to evolving technologies, and effectively secure their systems and data. Organizations in highly regulated industries and security-conscious organizations in both the public and private sectors that require strong authentication options should consider the OneWelcome Identity Platform.”

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,0001 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

_______________________________

1 Excluding Transport business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605617393/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye